Vertex Names Dr. Alan Garber, Provost of Harvard University, to its Board of Directors
June 08 2017 - 4:15PM
Business Wire
Shareholders of Vertex Pharmaceuticals
Incorporated (Nasdaq: VRTX) today elected Alan M. Garber,
M.D., Ph.D. as an independent member of its board of
directors. Dr. Garber is Provost of Harvard University, the
Mallinckrodt Professor of Health Care Policy at Harvard Medical
School, a Professor of Economics in the Faculty of Arts and
Sciences, a Professor of Public Policy in the Harvard Kennedy
School of Government, and a Professor in the Department of Health
Policy and Management in the Harvard T.H. Chan School of Public
Health.
“We are delighted that Alan is joining the Vertex Board. He
brings both his deep experience as an academic physician as well as
his expertise in health economics and the complexities of our
healthcare system to Vertex,” said Jeffrey Leiden, M.D.,
Ph.D., Chairman, President and Chief Executive Officer of Vertex.
“His insights and expertise will be invaluable as we continue to
deliver on our mission of bringing transformative medicines to more
people with cystic fibrosis and other serious diseases.”
“I am pleased to join the board of an organization that
endeavors to discover and deliver new medicines to treat
life-threatening diseases,” said Dr. Garber. “As a
physician-researcher, I look forward to working together to improve
the lives of people around the world.”
Prior to joining Harvard in 2011, Dr. Garber was the Henry J.
Kaiser Jr. Professor, a Professor of Medicine, and a Professor (by
courtesy) of Economics, Health Research and Policy, and of
Economics in the Graduate School of Business at Stanford
University. He is a member of the National Academy of Medicine, the
American Academy of Arts and Sciences, the American Society of
Clinical Investigation, the Association of American Physicians and
the Board on Science, Technology, and Economic Policy at the
National Academies. Dr. Garber is also a Fellow of the American
College of Physicians and the Royal College of Physicians and a
Research Associate with the National Bureau of Economic Research.
He also has served as a member of the National Advisory Council on
Aging at the National Institutes of Health, the Board of Health
Advisers of the Congressional Budget Office and Chair of the
Medicare Evidence Development and Coverage Advisory Committee at
the Centers for Medicare and Medicaid Services.
Dr. Garber holds an A.B. summa cum laude, an A.M. and a Ph.D. in
Economics from Harvard University, as well as an M.D. with research
honors from Stanford University.
About VertexVertex is a global biotechnology company that
aims to discover, develop and commercialize innovative medicines so
people with serious diseases can lead better lives. In addition to
our clinical development programs focused on cystic fibrosis,
Vertex has more than a dozen ongoing research programs aimed at
other serious and life-threatening diseases.
Founded in 1989 in Cambridge, Mass., Vertex today has research
and development sites and commercial offices in the United States,
Europe, Canada and Australia. For seven years in a row, Science
magazine has named Vertex one of its Top Employers in the life
sciences. For additional information and the latest updates from
the company, please visit www.vrtx.com.
(VRTX-GEN)
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170608006237/en/
Vertex Pharmaceuticals
IncorporatedInvestors:Michael Partridge, +1
617-341-6108orEric Rojas, +1 617-961-7205orZach Barber, +1
617-341-6470orMedia:mediainfo@vrtx.comNorth America: +1
617-341-6992orEurope & Australia: +44 20 3204 5275
Vertex Pharmaceuticals (NASDAQ:VRTX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Vertex Pharmaceuticals (NASDAQ:VRTX)
Historical Stock Chart
From Apr 2023 to Apr 2024